Coagulation, Haemostasis and interpretation of Coagulation tests

Similar documents
John Davidson Consultant in Intensive Care Medicine Freeman Hospital, Newcastle upon Tyne

TRANSFUSION GUIDELINES FOR CARDIOTHORACIC UNIT 2006

Emergency Management of Patients on Direct Oral Anticoagulants (DOACs)

Appendix 3 PCC Warfarin Reversal

Managing Coagulopathy in Intensive Care Setting

Prothrombin Complex Concentrate- Octaplex. Octaplex

GUIDELINES FOR MANAGEMENT OF BLEEDING AND EXCESSIVE ANTICOAGULATION WITH ORAL ANTICOAGULANTS

MANAGEMENT OF COAGULOPATHY AFTER TRAUMA OR MAJOR SURGERY

Management of haemorrhage in patients taking DOACs/ NOACs (direct/ novel oral anticoagulants) Guideline. Contents

Primary Exam Physiology lecture 5. Haemostasis

DOAC and NOAC are terms for a novel class of directly acting oral anticoagulant drugs including Rivaroxaban, Apixaban, Edoxaban, and Dabigatran.

Transfusion Requirements and Management in Trauma RACHEL JACK

New Age Anticoagulants: Bleeding Considerations

Dr Shikha Chattree Haematology Consultant Sunderland Royal infirmary

ANTICOAGULATION RELATED BLEEDING - GUIDELINE SUMMARY

Guidance for management of bleeding in patients taking the new oral anticoagulant drugs: rivaroxaban, dabigatran or apixaban

ACQUIRED COAGULATION ABNORMALITIES

Consensus Statement for Management of Anticoagulants and Antiplatelet drugs in Patients with Hip Fracture

Guidelines for the management of warfarin reversal in adults

Management of Challenging Bleeding: Patients with Coagulopathy

MANAGEMENT OF BLEEDING AND EXCESSIVE ANTICOAGULATION IN ADULTS RECEIVING ANTI-COAGULANTS

Challenges in Coagulation

Reversal of anticoagulation in GI Bleeding

Introduction to coagulation and laboratory tests

Active date July Ratification date: Review date January 2014 Applies to: Staff managing patients on warfarin. Exclusions:

General approach to the investigation of haemostasis. Jan Gert Nel Dept. of Haematology University of Pretoria 2013

Coagulation BEFORE Surgery

Effect of under filling tube

Major Haemorrhage Protocol. Commentary

When should I transfuse platelets and plasma for children? Dr Liz Chalmers. Consultant Paediatric Haematologist Royal Hospital for Children Glasgow

Approach to disseminated intravascular coagulation

Adult Reversal of Anticoagulation and Anti-platelet Agents for Life- Threatening Bleeding or Emergency Surgery Protocol

MANAGEMENT OF COMMON BLEEDING DISORDERS. Auro Viswabandya Department of Haematology, CMC, Vellore

ADMINISTRATIVE CLINICAL Page 1 of 6

DIC. Bert Vandewiele Fellow Critical Care 23 May 2011

Chapter 1 The Reversing Agents

Joost van Veen Consultant Haematologist

Praxbind-a novel anticoagulant reversal agent. Dr Mark Offer Consultant Haematologist

Surgery and Coagulopathy: pre-op assessment and optimisation. Dr Catherine Roughley Haemostasis Consultant Kent Haemophilia Centre, EKHUFT

DISSEMINATED INTRAVASCULAR COAGULATION (DIC) Pichika Chantrathammachart MD Division of Hematology, Department of Medicine Ramathibodi Hospital

Use of Prothrombin Complex Concentrates (PCC) CONTENTS

Appendix IV - Prescribing Guidance for Apixaban

Anticoagulation. MPharm Programme & OSPAP Programme. Tania Jones Senior Lecturer in Pharmacy Practice & Therapeutics

3/19/2012. What is the indication for anticoagulation? Has the patient previously been on warfarin? If so, what % of the time was the INR therapeutic?

Laboratory Empowerment. Debbie Asher Adrian Ebbs Transfusion Laboratory Managers, Eastern Pathology Alliance

Sysmex Educational Enhancement and Development No

The LaboratoryMatters

Disseminated Intravascular Coagulation. M.Bahmanpour MD Assistant professor IUMS

Use of Anticoagulant Reversal Agents

EMSS17: Bleeding patients course material

Hematology Review. CCRN exam. The Coagulation Cascade. The Coagulation Cascade. Components include: Intrinsic pathway Extrinsic pathway Common pathway

Debate: New Generation Anti-Coagulation Agents are a Better Choice than Warfarin in the Management of AF

L iter diagnostico di laboratorio nelle coagulopatie congenite emorragiche

PBM: The Future of Transfusion December 6 th 2012 East of England RTC. Sue Mallett Royal Free London NHS Foundation Trust

Trust Guideline for the Management of: Adult patients requiring anticoagulation with Warfarin (including reversal)

Blood Transfusion Guidelines in Clinical Practice

M B Garvey. University of Toronto

MASSIVE TRANSFUSION DR.K.HITESH KUMAR FINAL YEAR PG DEPT. OF TRANSFUSION MEDICINE

Reversal of Novel Oral Anticoagulants. Angelina The, MD March 22, 2016

Treatment of anticoagulant-associated intracerebral haemorrhage

ANTICOAGULANTS AND HIP FRACTURE SURGERY. Jon Antrobus Anaesthetist Borders General Hospital

Haemostasis & Coagulation disorders Objectives:

My Bloody Talk. Dr Ben Turner MBBS, FANZCA, FCICM The Royal Children s Hospital, Melbourne

How can ROTEM testing help you in trauma?

Blood coagulation and fibrinolysis. Blood clotting (HAP unit 5 th )

Agent Dose MoA/PK/Admin Adverse events Disadvantages Protamine Heparin: 1mg neutralizes ~ 100 units Heparin neutralization in ~ 5 min

Updates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism

Treatment Options and How They Work

Reversal of Anticoagulants at UCDMC

Oral Factor Xa Inhibitors and Clinical Laboratory Monitoring

10 Key Things the Vascular Community Should Know about the DOACs Heather Gornik, MD, RVT, RPVI

Intraoperative haemorrhage and haemostasis. Dr. med. Christian Quadri Capoclinica Anestesia, ORL

Blood Thinner Agent. Done by: Meznah Al-mutairi Pharm.D Candidate PNU Collage of Pharmacy

EDUCATIONAL COMMENTARY DISSEMINATED INTRAVASCULAR COAGULATION

COAGULATIONS. Dr. Hasan Fahmawi, MRCP(UK), FRCP(Edin)

Massive transfusion: Recent advances, guidelines & strategies. Dr.A.Surekha Devi Head, Dept. of Transfusion Medicine Global Hospital Hyderabad

Major Haemorrhage Transfusion Pathway

Hemostatic Resuscitation

Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc)

New Oral Anticoagulants in treatment of VTE, PE DR.AMR HANAFY (LECTURER OF CARDIOLOGY ) ASWAN UNIVERSITY

Early Management of the Patient with Acute GI Bleeding

Professional Practice Minutes December 7, 2016

Managing Bleeding in the Patient on DOACs

Disseminated intravascular coagulation (DIC) Dr. Klara Vezendi Szeged University Transfusiology Department

Clinical issues which drug for which patient

Laboratory monitoring of oral anticoagulants. A/Prof. Lee Lai Heng Haematology Singapore General Hospital

Diagnosis of hypercoagulability is by. Molecular markers

Trust Guideline for the Management of: Adult patients requiring anticoagulation with Warfarin (including reversal)

Mousa Suboh. Osama Alzoubi (OZ) Malik Zuhlof. 1 P a g e

Update on Oral Anticoagulants. Dr. Miten R. Patel Cancer Specialists of North Florida Cell

BLEEDING DISORDERS Simple complement:

Clinical Overview of Coagulation Testing Issues

MANAGEMENT OF OVERANTICOAGULATION AND PREOPERATIVE MANAGEMENT OF WARFARIN DOSE 1. GUIDELINES FOR THE MANAGEMENT OF AN ELEVATED INR

The effect of the direct oral anticoagulants (DOACs) on haemostasis tests.

Direct Oral Anticoagulants An Update

GUIDELINES FOR MANAGEMENT OF OVER ANTICOAGULATION WITH WARFARIN

BLEEDING DISORDERS. JC Opperman 2012

Index. Note: Page numbers of article titles are in boldface type.

Anticoagulation Cases. Dr J Mainwaring

Human Prothrombin Complex (PCC) (Beriplex P/N) in the emergency reversal of anticoagulation BCSLS Congress 2012 Kamloops, BC

Transcription:

Coagulation, Haemostasis and interpretation of Coagulation tests

Learning Outcomes Indicate the normal ranges for routine clotting screen and explain what each measurement means Recognise how to detect abnormal results and interpret possible causes Explain what further tests should be performed to help diagnose the cause of abnormal results Explain the use of TEG / RoTEM in monitoring haemostasis Review case studies of normal and abnormal and discuss results and outcomes with group

Haemostasis The vascular phase The platelet phase The coagulation phase

Major components of haemostasis https://www.thrombocyte.com/hemostasis-definition/

Clotting cascade

Simplified clotting cascade APTT measures XII, XI, IX, VIII, X, V, II, I Intrinsic pathway XII, XI, IX, VIII Common pathway X, V, II, I Extrinsic pathway VII Prothrombin Time measures VII, X, V, II, I Fibrin clot

How can we assess haemostasis? Clinical history and examination (e.g. haemostatic challenges) Laboratory tests Coagulation tests Viscoelastic haemostatic testing E.g. TEG/RoTEM

Laboratory: Clotting screening tests Coagulation screen

What do coagulation tests measure? APTT measures XII, XI, IX, VIII, X, V, II, I Intrinsic pathway XII, XI, IX, VIII Common pathway X, V, II, I Extrinsic pathway VII Prothrombin Time measures VII, X, V, II, I Fibrin clot

Prothrombin Time (13-15s) Measures extrinsic pathway Causes of prolonged PT include: Sepsis Warfarin therapy Vitamin K deficiency Liver disease DOACs Practical-haemostasis.com

Activated Partial Thromboplastin Time (APTT) (27-35s) Measures intrinsic pathway Causes of prolonged APTT: Sepsis DOACs Lupus Anticoagulant Heparins Single factor deficiencies Other With prolonged PT: Warfarin/Liver disease/dic

Thrombin Time (13-15s) Prolonged with: Unfractionated Heparin Fibrinogen deficiencies (acquired / congenital) Can have false reading with paraprotein Very prolonged with Dabigatran

Fibrinogen (1.5-4.0 g/l) Reduced in: DIC Massive haemorrhage Liver disease Post-thrombolysis Also reduced in congenital fibrinogen problems NB: usually raised in pregnancy

Reference ranges Physiology and coagulation factors alter with age Premature, newborn, young infants, children, adults different Local reference ranges for the hospital you work at Age range Developed for reagents and coagulation machine

What to do next? Investigations Repeat the sample (if time) If isolated PT check Factor VII level If APTT involved mixing studies Phone a friend the haematology team will help interpret results https://www.youtube.com/watch?v=pwnncir_nla

Management after that Deficiency Factor deficiency needs replacement Except factor XII/Contact factor deficiency If secondary to warfarin/doacs need reversal agents Inhibitors Lupus anticoagulant Other inhibitors rare but serious

Case 1 73yr old man for hip replacement, lives alone. Pre-op clinic bloods: PT 25 (11.5 13) APTT 33.2 (33 36)

What else would you like to know?

A Bleeding History In general: Ever had any haemostatic challenges eg surgery/dental extraction? Epistaxis/gum bleeding? Bruising/easy bleeding? Joint bleed / haematoma? (rare) Menorrhagia (not in this case!) Alcohol Drugs Family history

Causes of an isolated raised PT Warfarin Vitamin K deficiency Liver disease (acute) FVII deficiency (rare)

Case 2 16 year old boy in RTA, bike vs car. Not wearing helmet! GCS 10/15. CT confirms large subdural haematoma. Mum informs you on arrival that patient is on warfarin for Aortic valve replacement (metallic)

What are we going to do?

Warfarin Vitamin K antagonist. Reduces levels of factors II, VII, IX, and X. Long half life & takes a while to get to correct level Reversible with Vit K or PCC Monitored by INR (derived from the PT)

PCC (prothrombin complex concentrate) Fractionated blood component containing vitamin K dependent factors (II, VII, IX and X). Octaplex or Beriplex Given in conjunction with Vitamin K Works rapidly Is blood component, usually managed by blood bank Why do we need to give Vitamin K with PCC?

Warfarin reversal Check your local protocol!! For example only:

FFP is no longer used to reverse warfarin unless you do not have rapid access to PCC

WHAT DO WE DO WHEN HE S STABILISED?

Other anticoagulants: Direct Oral Anti-coagulants Dabigatran is a direct thrombin inhibitor Rivaroxaban/Apixaban/Edoxaban are direct factor Xa inhibitors. Licensed for VTE prophylaxis after hip/knee surgery, treatment of AF, treatment of VTE, prophylaxis after ACS, and more to come Tablets, work quickly, relatively short half life. Don't routinely need monitoring No antidote until recently Relatively expensive

DOAC Reversal As with warfarin, every Trust should have its own protocol for DOAC reversal in emergencies There is a specific reversal agent for Dabigatran idarucizumab (Praxbind) There are agents in the pipeline to reverse Xa inhibitors (none licensed yet) Discuss with Haematology

Low Molecular Weight Heparin (LMWH) i.e Clexane (enoxaparin) Fragmin (Dalteparin) Activates antithrombin Inhibition Thrombin (esp hep) Inhibition FXa Subcutaneous Short Half life Used for prophylaxis of VTE in hospital and treatment of VTE in acute setting Doesn t require monitoring usually Quick acting Partly reversible Renal excretion

Major haemorrhage Laboratory tests vs Near Patient Testing Viscoelastic haemostatic assays: +ves Bedside, rapid results Whole blood (can give indication about platelet function) Davenport et al

Near Patient Testing NICE Diagnostic Guideline 13 2014 www.nice.org ROTEM and TEG recommended to help monitor blood clotting during and after cardiac surgery by healthcare professionals with appropriate training Use as part of research studies in the emergency control of bleeding in trauma and obstetrics Guidance from British Society of Haematology published on use of VHA in 2018 https://onlinelibrary.wiley.com/doi/full/10.1111/bjh.15524

Major Haemorrhage - an example algorithm Trigger major haemorrhage alert Take baseline blood samples Tranexamic Acid TEAM LEADER - Oversees management Co-ordinator liaises with transfusion laboratory Request pre agreed ratio of blood components e.g : 4 units RBC & 4 units FFP IF BLEEDING CONTINUES If lab tests not available FFP and RBC in a ratio of 1:1 Consider Cryoprecipitate (2 pools) If lab tests available Give FFP 15ml/kg if PT/APTT ratio >1.5x normal Cryo 2pools if Fibrinogen <1.5g/l Platelets 1 unit if count <50x10 9 /l Continue monitoring with administration of blood components till bleeding stops

Case 3 35yr old lady Just given birth to baby boy, develops massive post partum haemorrhage After one hour, bleeding improves with local measures. However, bleeding then gets worse with oozing from venepuncture sites and epistaxis

Disseminated intravascular coagulopathy (DIC) Dysregulated fibrinolysis leading to widespread clotting ( using up the clotting factors), and resultant bleeding Patient usually very ill, with bleeding/bruising Prolonged PT/APTT Raised d-dimers Low platelets and fibrinogen.

Management of DIC ABC Treat underlying cause (vital) Blood product support usually only if bleeding (eg in this case) Ask Haematology for help Platelets, FFP, Cryo and Red Cells may all be appropriate

Learning Outcomes Indicate the normal ranges for routine clotting screen and explain what each measurement means Recognise how to detect abnormal results and interpret possible causes Explain what further tests should be performed to help diagnose the cause of abnormal results Explain the use of TEG / RoTEM in monitoring haemostasis Review case studies of normal and abnormal and discuss results and outcomes with group